GLP-1 수용체 작용제 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 용도별, 투여 경로별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)

GLP-1 Receptor Agonist Market Summary

The global GLP-1 receptor agonist market size was estimated at USD 70.08 billion in 2025 and is projected to reach USD 201.79 billion by 2033, growing at a CAGR of 12.78% from 2026 to 2033. The launch of new glucagon-like peptide 1 (GLP-1) receptor agonist products, a robust product pipeline for both diabetes & obesity applications, and the high efficacy of these drugs are anticipated to propel market growth.

In May 2024, Innovent Biologics announced that its type 2 diabetes candidate, mazdutide, outperformed Eli Lilly's Trulicity (dulaglutide) in a Phase III trial. The study established that mazdutide was superior in glycemic control and provided numerous cardiometabolic benefits, comprising weight loss & improvements in blood lipid levels, liver enzymes, serum uric acid, & blood pressure.

Other companies, such as Boehringer Ingelheim International GmbH, Carmot Therapeutics, Inc., D&D Pharmatech, Eli Lilly and Company (Lilly), and Hanmi Pharm. Co., Ltd, are also involved in developing new glucagon-like peptide 1 drugs. For instance, in October 2023, Carmot Therapeutics, Inc. published preliminary results from the single ascending dose (SAD) phase of an ongoing Phase 1 clinical trial for CT-996, an oral small molecule GLP-1 receptor agonist (RA) that is presently being assessed in a first-in-human clinical trial in individuals who are overweight or obese. Thus, increasing research in the field of GLP-1 receptor agonists is expected to drive market growth.

Moreover, the rising prevalence of obesity and diabetes is expected to drive the growth of the GLP-1 receptor agonist industry. The overweight and obese population is at a high risk of developing diabetes and cardiovascular illness. Worldwide obesity rates are rising, and it is widely acknowledged that this is one of the major public health issues of the present day. According to the World Heart Federation's global estimate, almost 2.3 billion children and adults worldwide suffer from obesity and overweight. Additionally, according to the Obesity Action Coalition (OAC), over 90% of individuals diagnosed with type 2 diabetes are either overweight or have some degree of obesity. Therefore, the rising obese and diabetes populations are driving the demand for GLP-1 receptor agonist drugs for treatment worldwide.

The high advantages associated with the use of GLP-1 drugs over other medicines, along with increasing investment in the R&D of new GLP-1 drugs, are driving market growth. Several GLP agonists have been linked to weight loss or weight neutrality, which is advantageous for people with diabetes since obesity frequently makes the disease worse. The lowering of appetite and the delayed stomach emptying contribute to the weight loss effect. Moreover, in November 2023, Novo Nordisk announced its intention to invest approximately 16 billion Danish kroner in developing GLP-1 drugs. This is roughly equivalent to USD 2.32 billion (€2.14 billion). These initiatives are anticipated to drive the market's growth.

Global GLP-1 Receptor Agonist Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global GLP-1 Receptor Agonist market report based on product, application, route of administration, distribution channel, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Ozempic
• Trulicity
• Mounjaro
• Wegovy
• Rybelsus
• Saxenda
• Victoza
• Zepbound
• Other Products
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Type 2 Diabetes Mellitus
• Obesity
• Route of administration Outlook (Revenue, USD Million, 2021 - 2033)
• Parenteral
• Oral
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Kuwait
  • UAE

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and Application Outlook
  • 2.2.2. Route of Administration and Distribution Channel Outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. GLP-1 Receptor Agonist Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases such as diabetes and obesity
    • 3.2.1.2. Increasing R&D activities for developing novel therapeutics
    • 3.2.1.3. Formulation advancements of oral GLP-1 receptor agonists
    • 3.2.1.4. Increasing awareness about diagnosis and treatment options for diabetes
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Product failure
    • 3.2.2.2. Patent expiry of blockbuster drugs during the forecast period
• 3.3. GLP-1 Receptor Agonist Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Pricing Analysis
• 3.5. Pipeline Analysis
• 3.6. Patent Expiry Analysis

Chapter 4. GLP-1 Receptor Agonist Market: Product Estimates & Trend Analysis

• 4.1. Global GLP-1 Receptor Agonist Market: Product Dashboard
• 4.2. Global GLP-1 Receptor Agonist Market: Product Movement Analysis
• 4.3. Ozempic
  • 4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.4. Rybelsus
  • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Trulicity
  • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Saxenda
  • 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.7. Wegovy
  • 4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.8. Victoza
  • 4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.9. Mounjaro
  • 4.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.10. Zepbound
  • 4.10.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.11. Others
  • 4.11.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. GLP-1 Receptor Agonist Market: Application Estimates & Trend Analysis

• 5.1. Global GLP-1 Receptor Agonist Market: Application Dashboard
• 5.2. Global GLP-1 Receptor Agonist Market: Application Movement Analysis
• 5.3. Type 2 Diabetes Mellitus
  • 5.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.4. Obesity
  • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. GLP-1 Receptor Agonist Market: Route of Administration Estimates & Trend Analysis

• 6.1. Global GLP-1 Receptor Agonist Market: Route of Administration Dashboard
• 6.2. Global GLP-1 Receptor Agonist Market: Route of Administration Movement Analysis
• 6.3. Parenteral
  • 6.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 6.4. Oral
  • 6.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. GLP-1 Receptor Agonist Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Global GLP-1 Receptor Agonist Market: Distribution Channel Dashboard
• 7.2. Global GLP-1 Receptor Agonist Market: Distribution Channel Movement Analysis
• 7.3. Hospital Pharmacies
  • 7.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 7.4. Retail Pharmacies
  • 7.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Online Pharmacies
  • 7.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. GLP-1 Receptor Agonist Market: Regional Estimates & Trend Analysis By Product, Application, Route of Administration, and Distribution Channel

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.6. Denmark
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.8. Norway
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Participant Overview
• 9.3. Financial Overview
• 9.4. Product Benchmarking
• 9.5. Company Market Share Analysis, 2025
• 9.6. Strategy Mapping
• 9.7. Company Profiles
  • 9.7.1. Eli Lilly and Company.
    • 9.7.1.1. Company overview
    • 9.7.1.2. Financial performance
    • 9.7.1.3. benchmarking
    • 9.7.1.4. Strategic initiatives
  • 9.7.2. Sanofi
    • 9.7.2.1. Company overview
    • 9.7.2.2. Financial performance
    • 9.7.2.3. benchmarking
    • 9.7.2.4. Strategic initiatives
  • 9.7.3. Novo Nordisk A/S
    • 9.7.3.1. Company overview
    • 9.7.3.2. Financial performance
    • 9.7.3.3. benchmarking
    • 9.7.3.4. Strategic initiatives
  • 9.7.4. AstraZeneca.
    • 9.7.4.1. Company overview
    • 9.7.4.2. Financial performance
    • 9.7.4.3. benchmarking
    • 9.7.4.4. Strategic initiatives